Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Purchased by Teacher Retirement System of Texas

Teacher Retirement System of Texas boosted its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 18.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 109,531 shares of the company’s stock after buying an additional 16,891 shares during the period. Teacher Retirement System of Texas’ holdings in Roivant Sciences were worth $1,296,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Nordea Investment Management AB increased its holdings in shares of Roivant Sciences by 22.5% during the fourth quarter. Nordea Investment Management AB now owns 282,834 shares of the company’s stock valued at $3,306,000 after acquiring an additional 52,031 shares in the last quarter. TOMS Capital Investment Management LP purchased a new stake in Roivant Sciences during the 3rd quarter worth approximately $46,333,000. Barclays PLC increased its stake in Roivant Sciences by 19.7% during the 3rd quarter. Barclays PLC now owns 459,521 shares of the company’s stock valued at $5,302,000 after purchasing an additional 75,609 shares in the last quarter. Retirement Systems of Alabama raised its holdings in shares of Roivant Sciences by 26.9% in the third quarter. Retirement Systems of Alabama now owns 530,022 shares of the company’s stock worth $6,116,000 after buying an additional 112,286 shares during the last quarter. Finally, Elevate Capital Advisors LLC acquired a new stake in shares of Roivant Sciences during the fourth quarter worth $2,116,000. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Roivant Sciences Stock Performance

NASDAQ ROIV opened at $10.38 on Friday. The firm has a market capitalization of $7.41 billion, a P/E ratio of -69.20 and a beta of 1.26. The stock has a 50-day simple moving average of $10.74 and a two-hundred day simple moving average of $11.41. Roivant Sciences Ltd. has a fifty-two week low of $9.96 and a fifty-two week high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. As a group, analysts forecast that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on ROIV shares. Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a research report on Tuesday, March 4th. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a research note on Tuesday, February 11th. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $17.10.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, Director Sciences Ltd. Roivant purchased 16,845,010 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The stock was purchased at an average price of $20.00 per share, for a total transaction of $336,900,200.00. Following the purchase, the director now directly owns 96,650,341 shares in the company, valued at approximately $1,933,006,820. This trade represents a 21.11 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Eric Venker sold 100,000 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $11.28, for a total value of $1,128,000.00. Following the transaction, the chief operating officer now owns 732,294 shares in the company, valued at $8,260,276.32. This represents a 12.01 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,573,245 shares of company stock worth $17,079,242 in the last three months. Company insiders own 7.90% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.